Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

BACKGROUND: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, Edison, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448216/
https://www.ncbi.nlm.nih.gov/pubmed/30944040
http://dx.doi.org/10.1186/s13063-019-3259-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448216/
https://www.ncbi.nlm.nih.gov/pubmed/30944040
http://dx.doi.org/10.1186/s13063-019-3259-x

Ejemplares similares